Colorado BioScience Association04.27.16
Colorado BioScience Association (CBSA), a not-for-profit corporation providing services and support for Colorado's biotechnology, life science, medical device, agbio, and pharmaceutical industries, has named a new slate of board members representing the state’s medical device and pharmaceutical companies, research institutions, and service providers supporting the life science sector. The five new board members were approved during the CBSA annual board retreat on April 20.
The new members bring a wealth of experience in life science from careers in research, marketing and regulatory affairs, as well as corporate growth and financial management.
Newly appointed board members include:
Board members renewing their terms include:
Current board members moving onto the executive committee include:
“As the life science sector in Colorado continues to grow and evolve rapidly, we welcome Bobbi, Terry, Terri, Mark and Dan to help us architect the future for CBSA and our members,” said Mark Spiecker, board chairman of CBSA. “I’m also pleased to collaborate more closely with Alan, Ginny, and Dustin on the executive committee, and look forward to tapping their expertise to support CBSA members.”
“We look forward to new ideas, opportunities for partnership and growth strategies with the addition of our new board members,” said April Giles, president and CEO of CBSA. “We also want to thank our outgoing board members for their dedication to the Colorado BioScience Association, with a special thanks to our former board chairman Derek Cole for his dedicated service to CBSA.”
The new members bring a wealth of experience in life science from careers in research, marketing and regulatory affairs, as well as corporate growth and financial management.
Newly appointed board members include:
- Bobbi Coffin, Biodesix, vice president of commercial marketing.
- Terry Dagnon, Dohmen Life Science Services, senior vice president, Denver operations.
- Terri Fiez, Ph.D., University of Colorado-Boulder, vice chancellor for research and innovation.
- Mark Messenbaugh, SomaLogic, executive director, corporate strategy and development.
- Dan Muehl, Clovis Oncology, vice president of finance and principal financial and accounting officer.
Board members renewing their terms include:
- Bruce Eaton, Ph.D., i2 Pharmaceuticals Inc., president and CEO.
- Scott Larson, Terumo BCT, senior vice president, legal and general counsel.
- Bill Marshall, Ph.D., miRagen Therapeutics, president, CEO, co-founder and director.
- Chris Myatt, Ph.D., MBio Diagnostics, CEO.
- Ginny Orndorff, CID4, executive director and CEO.
Current board members moving onto the executive committee include:
- Alan Rudolph, Ph.D., Colorado State University, vice president for research.
- Ginny Orndorff, CID4, executive director and CEO.
- Dustin Whistler, Forte Commercial Real Estate, founder and principal.
“As the life science sector in Colorado continues to grow and evolve rapidly, we welcome Bobbi, Terry, Terri, Mark and Dan to help us architect the future for CBSA and our members,” said Mark Spiecker, board chairman of CBSA. “I’m also pleased to collaborate more closely with Alan, Ginny, and Dustin on the executive committee, and look forward to tapping their expertise to support CBSA members.”
“We look forward to new ideas, opportunities for partnership and growth strategies with the addition of our new board members,” said April Giles, president and CEO of CBSA. “We also want to thank our outgoing board members for their dedication to the Colorado BioScience Association, with a special thanks to our former board chairman Derek Cole for his dedicated service to CBSA.”